Table 1.
Baseline characteristics at diagnosis
| Characteristics | Global series (N = 268) | R‐CHOP/21 cohort3 (n = 203) |
|---|---|---|
| Age at diagnosis, median (range) | 61 (18–85) | 61 (18–85) |
| Female/male, n (%) | 135 (50.4)/133 (49.6) | 102 (50.2)/101 (49.8) |
| WBC (×10E9/L), median (range) | 7 (1.3–28.2) | 6.9 (1.3–20.8) |
| Hb (g/dL), median (range) | 12.2 (7.6–16.7) | 12.4 (7.7–16.7) |
| Platelets (×10E9/L), median (range) | 250 (15–965) | 245 (27–802) |
| B2microglobulin [ULN]1, n (%) | 145 (54.1) | 104 (51.2) |
| LDH [ULN]2, n (%) | 176 (65.7) | 131 (64.5) |
| ECOG PS, n (%) | ||
| 0–1 | 222 (82.8) | 175 (86.2) |
| 2–4 | 46 (17.2) | 28 (13.8) |
| B symptoms, n (%) | 88 (32.8) | 61 (30.0) |
| Stage (Ann Arbor), n (%) | ||
| I–II | 67 (25.0) | 51 (25.1) |
| III–IV | 201 (75.0) | 152 (74.9) |
| Bulky mass [≥10 cm], n (%) | 72 (26.9) | 51 (25.1) |
| Extranodal involvement (sites), n (%) | ||
| 0–1 | 215 (80.2) | 168 (82.8) |
| ≥2 | 53 (19.8) | 35 (17.2) |
| Splenomegaly, n (%) | 73 (27.2) | 52 (25.6) |
| IPI, n (%) | ||
| Low (0, 1) | 74 (27.6) | 60 (29.6) |
| Low‐intermediate (2) | 82 (30.6) | 60 (29.6) |
| High‐intermediate (3) | 66 (24.6) | 55 (27.1) |
| High (4, 5) | 46 (17.2) | 28 (13.8) |
| BMI by BMB, n (%) | 35 (13.1) | 26 (12.8) |
| BMI by PET/CT, n (%) | 60 (22.4) | 42 (20.7) |
| Diffuse | 15 (5.6) | 10 (4.9) |
| Focal | 45 (16.8) | 32 (15.8) |
| Unifocal | 9 (3.4) | 8 (3.9) |
| Multifocal | 36 (13.4) | 24 (11.8) |
| SUV max, median (p25–p75) | ||
| Diffuse | 6.7 (4.3–9.8) | 6.8 (5.1–9.8) |
| Focal | 9.8 (6.3–15.3) | 10.6 (4.9–16.0) |
ECOG PS, Eastern cooperative oncology group performance score; LDH, lactate dehydrogenase; ULN, upper limit of normal (1B2microglobulin > 2.5 mg/L and 2LDH>250 UI/L); IPI, international prognosis index; BMI, bone marrow involvement; BMB, bone marrow biopsy; PET/CT, positron emission tomography/computed tomography; SD, standard deviation.
3Patients treated with R‐CHOP/21 as first‐line therapeutic strategy.